-
公开(公告)号：US20240335550A1
公开(公告)日：2024-10-10
申请号：US18628261
申请日：2024-04-05
IPC分类号： A61K47/64 , A61K9/00 , A61K9/70 , A61K31/165 , A61K31/513 , A61K31/573 , A61K31/58 , A61K41/00
CPC分类号： A61K47/6435 , A61K9/006 , A61K9/7007 , A61K31/165 , A61K31/513 , A61K31/573 , A61K31/58 , A61K41/0042
摘要： Mucosal patches are disclosed that have a support layer supporting an active layer that has a collagen carbon dot nanocomposite carrying an active agent. The collagen carbon dot nanocomposite is absorbable through a mucosa. The mucosal patches are part of various methods of treatment.
-
公开(公告)号：US20240197912A1
公开(公告)日：2024-06-20
申请号：US18565162
申请日：2022-06-03
申请人： MAGLE CHEMOSWED AB
发明人： Håkan NYGREN
IPC分类号： A61K48/00 , A61K9/06 , A61K38/17 , A61K38/18 , A61K38/22 , A61K38/39 , A61K38/45 , A61K38/48 , A61K47/52 , A61K47/61 , A61K47/64
CPC分类号： A61K48/0041 , A61K9/06 , A61K38/1716 , A61K38/177 , A61K38/1777 , A61K38/18 , A61K38/1875 , A61K38/2271 , A61K38/39 , A61K38/45 , A61K38/482 , A61K38/4886 , A61K47/52 , A61K47/61 , A61K47/6435
摘要： A pharmaceutically acceptable aqueous gel composition comprising a gelling agent, magnesium and/or manganese, or bivalent ions thereof, and an mRNA molecule encoding a protein of interest; and methods for inducing or facilitating repair, re-generation or generation of tissue in a human or animal subject, comprising administering the composition to the site of the tissue to be repaired, re-generated or generated.
-
公开(公告)号：US20240092867A1
公开(公告)日：2024-03-21
申请号：US18352101
申请日：2023-07-13
发明人： Jeffrey A. HUBBELL , Anna M. RANDI , Jun ISHIHARA , Ako ISHIHARA , Priscilla BRIQUEZ , Richard STARKE
IPC分类号： C07K14/78 , A61K9/00 , A61K9/70 , A61K38/00 , A61K38/18 , A61K38/39 , A61K47/64 , A61K47/69 , A61L27/22 , A61P17/02 , C07K14/475 , C07K14/705 , C07K14/81 , C07K16/18
CPC分类号： C07K14/78 , A61K9/0024 , A61K9/7007 , A61K38/00 , A61K38/18 , A61K38/39 , A61K47/6435 , A61K47/6903 , A61L27/22 , A61P17/02 , C07K14/475 , C07K14/70546 , C07K14/8121 , C07K16/18 , A61L2300/412 , C07K2317/55 , C07K2319/70
摘要： The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80% identical to one of SEQ ID NOS:1-7, 13-15, 49-50, or 66-70, or a fragment thereof; wherein the peptide is less than 300 amino acids in length.
-
公开(公告)号：US20230405136A1
公开(公告)日：2023-12-21
申请号：US18029913
申请日：2021-10-04
IPC分类号： A61K47/64 , A61K47/69 , A61P21/00 , A61K47/54 , A61K9/00 , A61K47/65 , A61K47/61 , A61K47/52
CPC分类号： A61K47/6435 , A61K47/6903 , A61K47/6929 , A61P21/00 , A61K47/52 , A61K9/0014 , A61K47/545 , A61K47/65 , A61K47/61 , A61K47/54
摘要： Combinations of boron compounds and adjuvants and compositions thereof are suitable for use in a method to induce myotube formation and suppress cell mortality in a mammal in need thereof and for the treatment of epithelial cancers. Compositions comprise boron compounds, adjuvants and support platforms, which enhance the effect of synergistic activation of the boron cell membrane transporter (NaBC1) and adhesion receptors in cells. The combinations and compositions are for the treatment of pathophysiological condition, which affects skeletal muscle, such as dystrophy and epithelial cancer. The combinations and compositions can be included in the field of medical chemistry or pharmacology.
-
公开(公告)号：US20230279068A1
公开(公告)日：2023-09-07
申请号：US18074275
申请日：2022-12-02
IPC分类号： C07K14/51 , A61K47/64 , C07K14/78 , A61K47/60 , A61K38/18 , C07K14/47 , C07K14/49 , C07K14/50 , C07K14/575 , C07K14/65 , C07K14/79 , C12N9/12 , C12N9/54 , C12N9/74
CPC分类号： C07K14/51 , A61K38/1875 , A61K47/60 , A61K47/6435 , A61K47/645 , C07K14/47 , C07K14/4721 , C07K14/49 , C07K14/50 , C07K14/575 , C07K14/65 , C07K14/78 , C07K14/79 , C12N9/12 , C12N9/54 , C12N9/6429 , A61K38/00
摘要： The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.
-
公开(公告)号：US20190077844A1
公开(公告)日：2019-03-14
申请号：US15760449
申请日：2016-09-22
发明人： Dasa LIPOVSEK , Joseph TOTH , Ginger C. RAKESTRAW , Irvith M. CARVAJAL , Stanley Richard KRYSTEK, JR. , Steven R. O'NEIL , Guodong CHEN , Richard Y. HUANG , Bryan C. BARNHART , John Thomas LOFFREDO , Christina TERRAGNI
CPC分类号： C07K14/78 , A61K38/00 , A61K47/60 , A61K47/64 , A61K47/6435 , G01N33/6872
摘要： Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
-
公开(公告)号：US09919032B2
公开(公告)日：2018-03-20
申请号：US15355386
申请日：2016-11-18
CPC分类号： A61K38/2278 , A61K9/0019 , A61K38/00 , A61K38/16 , A61K38/26 , A61K38/28 , A61K45/06 , A61K47/02 , A61K47/183 , A61K47/42 , A61K47/6435
摘要： The present invention provides pharmaceutical formulations for sustained release when administered at cold temperatures, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.
-
公开(公告)号：US20170354741A1
公开(公告)日：2017-12-14
申请号：US15524931
申请日：2015-10-30
发明人： Clyde M. OFNER III , Chris CAMMARATA , Brian RHODES , Darren WU
IPC分类号： A61K47/64
CPC分类号： A61K47/6435 , A61K31/704 , A61K47/64 , A61K47/65 , A61K47/6903
摘要： Disclosed herein are high molecular weight compounds comprising gelatin and doxorubicin, where the gelatin is covalently linked to doxorubicin through a cleavable linker. The cleavable linker can be cleaved under appropriate physiological conditions, and thus lead to the freeing of doxorubicin. The free doxorubicin can then exert its cytotoxic effects on cancer cells. Disclosed herein are methods of making the high molecular weight gelatin-doxorubicin conjugates and methods of use of the same.
-
公开(公告)号：US09629920B2
公开(公告)日：2017-04-25
申请号：US13517024
申请日：2010-12-17
IPC分类号： A61K47/48 , A61K9/00 , A61K47/42 , A61K9/16 , A61K31/4468 , A61K45/06 , A61K9/50 , A61K31/192
CPC分类号： A61K47/48246 , A61K9/0095 , A61K9/1658 , A61K9/5089 , A61K31/192 , A61K31/4468 , A61K45/06 , A61K47/42 , A61K47/64 , A61K47/643 , A61K47/6435 , A61K47/644 , A61K47/68
摘要： The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention also provides a method of administering the composition, such as to a patient with dysphasia; liquid or semi-solid formulations of the composition; methods for preparing the composition; and kits including the composition.
-
公开(公告)号：US20170049905A1
公开(公告)日：2017-02-23
申请号：US15253358
申请日：2016-08-31
发明人： Bernice YEUNG , Jack Wang
CPC分类号： A61K38/02 , A61K47/60 , A61K47/6435 , C07K14/78
摘要： Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage.
摘要翻译： 本文描述的是在储存期间维持聚乙二醇化和抑制多肽例如基于纤连蛋白的支架蛋白的去磷酸化的方法。
-
-
-
-
-
-
-
-
-
搜索结果
181 条记录 (耗时 0.179 秒)
